Phase 2
N=11
VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation
COVID-19
Bottom Line
View on ClinicalTrials.gov: NCT04452669 ↗Enrolled (actual)
11
Serious AEs
45.5%
Results posted
Jul 2025
Primary outcome: Primary: Change in Respiratory Failure — 3; 2 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Aerogen Pharma Limited
- Primary completion
- Jun 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Respiratory Failure |
3; 2 | — |
| PRIMARY Change in Cardiac/Circulatory Failure |
0; 0 | — |
Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Eligibility Criteria
Inclusion Criteria
- Confirmed COVID-19 positive by RT-PCR test
- Patients who require invasive mechanical ventilation.
- Consent or professional consent obtained
Exclusion Criteria
- Patients on ECMO support.
- Patients receiving another inhalation research medication or inhaled nitric oxide.
- Not expected to survive for 48 hours.
- Allergy to Epoprostenol and its diluent
Data sourced from ClinicalTrials.gov (NCT04452669). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.